A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

NCT01562743 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Restless Legs Syndrome

Interventions

DRUG: SPM 962

Sponsor

Otsuka Pharmaceutical Co., Ltd.